May 2018 Issue Table Of Contents

From The Editor

• Is Silence Golden?

Feature Articles

• Industry Explorers Blaze On: Anna Protopapas
• Kaleido Biosciences: The Opportunity That Pulled Michael Bonney Out Of Retirement

Capitol Perspectives

• Congress Tackles The Opioid Crisis

Companies To Watch

• Landos Biopharma

CEO Corner

• Leaders In Biotech: Raising Our Voices Beyond Industry’s Walls

From Principles and Policy to Execution

• Policy Initiatives To Improve Population Health

Industry Research

• Trial Data Collection: Paper Vs. Electronic

Inside The Industry

• How Biotechs Can Avoid The Common Pitfalls Of Going Public
• Compliant Cocreation Key For Digital Innovation
• In Two Months, Gene Therapy Startup Raises $100 Million
• Brand Strength And The Contract Manufacturing Competitive Landscape
• Cultivating An R&D Ecosystem: Thriving Through Collaboration
• J&J’s QuickFire Challenges: Crowdsourcing Innovation
• State Of A Nation: The UK Is Facing Up To Global Drug Discovery Challenges

Leadership Lessons

• Fixing Healthcare Costs (And Turnover And Productivity Issues) Starts In The Workplace

Ask The Board

• Is There Any Form Of Drug-Pricing Legislation You Could Get Behind, And, If So, What Would It Look Like?
• Knowing How Many Companies Use Various Social Media Outlets For Communications, What Impact Does The Recent Cambridge Analytica And Facebook Scandal Have On Our Company And Our Industry As A Whole?
• What Should I Know Before I Choose A Career (Even Part Time) In Consulting?